Genetic association studies in mood disorders: Issues and promise

Sevilla D. Detera-Wadleigh, Francis J. McMahon

Research output: Contribution to journalArticle

Abstract

Genetic association is a powerful method for identifying genetic variants that contribute to the molecular basis of complex diseases. There is now a wealth of informative, validated and densely-spaced single nucleotide polymorphism (SNP) markers for use in association studies, and the delineation of the genome-wide haplotype architecture will greatly enhance our ability to conduct whole genome association screens, fine mapping of linkage regions, and systematic screening of functional candidate genes. Single nucleotide polymorphism-based genotyping technology has progressed dramatically to the point of high-throughput methods that can assay up to thousands of SNPs on many samples in one experiment. Genotyping cost remains a limiting factor in complex disease studies, where numerous SNPs and large sample sets are needed to maximize statistical power. Strategies designed to reduce cost include DNA pooling and analysis with tagSNPs. As larger clinical samples become available, it will be increasingly important to test for hidden stratification in case-control studies, as well as transmission distortion in family-based studies, either of which can lead to spurious association findings. As yet, there is no widely-accepted genetic association finding in mood disorders, but functional candidate genes, such as the serotonin transporter, and positional candidates, such as G72/G30 on chromosome 13q, are beginning to be identified in several studies. Relating associated variants to the phenotype represents the next critical step toward establishing the pathogenic role of gene variants in mood disorders.

Original languageEnglish (US)
Pages (from-to)301-310
Number of pages10
JournalInternational Review of Psychiatry
Volume16
Issue number4
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Genetic Association Studies
Mood Disorders
Single Nucleotide Polymorphism
Genes
Costs and Cost Analysis
Serotonin Plasma Membrane Transport Proteins
Aptitude
Chromosome Mapping
Genome-Wide Association Study
Haplotypes
Case-Control Studies
Chromosomes
Genome
Technology
Phenotype
DNA

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Genetic association studies in mood disorders : Issues and promise. / Detera-Wadleigh, Sevilla D.; McMahon, Francis J.

In: International Review of Psychiatry, Vol. 16, No. 4, 11.2004, p. 301-310.

Research output: Contribution to journalArticle

Detera-Wadleigh, Sevilla D. ; McMahon, Francis J. / Genetic association studies in mood disorders : Issues and promise. In: International Review of Psychiatry. 2004 ; Vol. 16, No. 4. pp. 301-310.
@article{5fd4cbf04f194d58bac434415f44d271,
title = "Genetic association studies in mood disorders: Issues and promise",
abstract = "Genetic association is a powerful method for identifying genetic variants that contribute to the molecular basis of complex diseases. There is now a wealth of informative, validated and densely-spaced single nucleotide polymorphism (SNP) markers for use in association studies, and the delineation of the genome-wide haplotype architecture will greatly enhance our ability to conduct whole genome association screens, fine mapping of linkage regions, and systematic screening of functional candidate genes. Single nucleotide polymorphism-based genotyping technology has progressed dramatically to the point of high-throughput methods that can assay up to thousands of SNPs on many samples in one experiment. Genotyping cost remains a limiting factor in complex disease studies, where numerous SNPs and large sample sets are needed to maximize statistical power. Strategies designed to reduce cost include DNA pooling and analysis with tagSNPs. As larger clinical samples become available, it will be increasingly important to test for hidden stratification in case-control studies, as well as transmission distortion in family-based studies, either of which can lead to spurious association findings. As yet, there is no widely-accepted genetic association finding in mood disorders, but functional candidate genes, such as the serotonin transporter, and positional candidates, such as G72/G30 on chromosome 13q, are beginning to be identified in several studies. Relating associated variants to the phenotype represents the next critical step toward establishing the pathogenic role of gene variants in mood disorders.",
author = "Detera-Wadleigh, {Sevilla D.} and McMahon, {Francis J.}",
year = "2004",
month = "11",
doi = "10.1080/09540260400014377",
language = "English (US)",
volume = "16",
pages = "301--310",
journal = "International Review of Psychiatry",
issn = "0954-0261",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Genetic association studies in mood disorders

T2 - Issues and promise

AU - Detera-Wadleigh, Sevilla D.

AU - McMahon, Francis J.

PY - 2004/11

Y1 - 2004/11

N2 - Genetic association is a powerful method for identifying genetic variants that contribute to the molecular basis of complex diseases. There is now a wealth of informative, validated and densely-spaced single nucleotide polymorphism (SNP) markers for use in association studies, and the delineation of the genome-wide haplotype architecture will greatly enhance our ability to conduct whole genome association screens, fine mapping of linkage regions, and systematic screening of functional candidate genes. Single nucleotide polymorphism-based genotyping technology has progressed dramatically to the point of high-throughput methods that can assay up to thousands of SNPs on many samples in one experiment. Genotyping cost remains a limiting factor in complex disease studies, where numerous SNPs and large sample sets are needed to maximize statistical power. Strategies designed to reduce cost include DNA pooling and analysis with tagSNPs. As larger clinical samples become available, it will be increasingly important to test for hidden stratification in case-control studies, as well as transmission distortion in family-based studies, either of which can lead to spurious association findings. As yet, there is no widely-accepted genetic association finding in mood disorders, but functional candidate genes, such as the serotonin transporter, and positional candidates, such as G72/G30 on chromosome 13q, are beginning to be identified in several studies. Relating associated variants to the phenotype represents the next critical step toward establishing the pathogenic role of gene variants in mood disorders.

AB - Genetic association is a powerful method for identifying genetic variants that contribute to the molecular basis of complex diseases. There is now a wealth of informative, validated and densely-spaced single nucleotide polymorphism (SNP) markers for use in association studies, and the delineation of the genome-wide haplotype architecture will greatly enhance our ability to conduct whole genome association screens, fine mapping of linkage regions, and systematic screening of functional candidate genes. Single nucleotide polymorphism-based genotyping technology has progressed dramatically to the point of high-throughput methods that can assay up to thousands of SNPs on many samples in one experiment. Genotyping cost remains a limiting factor in complex disease studies, where numerous SNPs and large sample sets are needed to maximize statistical power. Strategies designed to reduce cost include DNA pooling and analysis with tagSNPs. As larger clinical samples become available, it will be increasingly important to test for hidden stratification in case-control studies, as well as transmission distortion in family-based studies, either of which can lead to spurious association findings. As yet, there is no widely-accepted genetic association finding in mood disorders, but functional candidate genes, such as the serotonin transporter, and positional candidates, such as G72/G30 on chromosome 13q, are beginning to be identified in several studies. Relating associated variants to the phenotype represents the next critical step toward establishing the pathogenic role of gene variants in mood disorders.

UR - http://www.scopus.com/inward/record.url?scp=10644280004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644280004&partnerID=8YFLogxK

U2 - 10.1080/09540260400014377

DO - 10.1080/09540260400014377

M3 - Article

C2 - 16194763

AN - SCOPUS:10644280004

VL - 16

SP - 301

EP - 310

JO - International Review of Psychiatry

JF - International Review of Psychiatry

SN - 0954-0261

IS - 4

ER -